Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRICKET: ctDNA-guided encorafenib + cetuximab retreatment in BRAF V600E metastatic colorectal cancer
2023-509088-26-00Phase 2Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and cetuximab in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Objective response rate. Started Jul 2024; status: completed.
02
Drugs
encorafenibcetuximab
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2023-509088-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509088-26-00.